Familial Nonmedullary Thyroid Carcinoma: Disease-Characteristics Report

Executive summary

Familial nonmedullary thyroid carcinoma (FNMTC) is familial aggregation of follicular-cell-derived thyroid carcinoma—predominantly papillary thyroid carcinoma (PTC)—rather than medullary thyroid carcinoma. The conventional clinical definition is NMTC in at least two first-degree relatives, after excluding a recognized tumor-predisposition syndrome. However, only an estimated 31–38% of two-case families may represent true inherited disease, versus approximately 96% of families with at least three affected members. Thus, ≥3 affected relatives is a more specific research definition. FNMTC comprises roughly 5–15% of NMTC in recent reviews; approximately 5% of familial cases are explained by recognized syndromes, while most nonsyndromic cases remain genetically unresolved. (yang2016familialnonmedullarythyroid pages 13-14, sanchezares2022susceptibilitygenesand pages 1-2, kamani2022geneticsusceptibilityto pages 1-2)

The principal current conclusion is that nonsyndromic FNMTC is not one Mendelian disorder. It is genetically heterogeneous, usually modeled as autosomal-dominant susceptibility with incomplete, age-dependent penetrance and variable expressivity, or as a polygenic trait. No single germline gene explains most isolated families. Confirmed, clinically actionable genes mainly belong to syndromic disease—APC, PTEN, DICER1, PRKAR1A, and WRN—whereas FOXE1, SRGAP1, NKX2-1, HABP2, MAP2K5, DUOX2, CHEK2, POT1 and numerous other candidates require family-specific interpretation and, for many, independent replication. (capezzone2021familialnonmedullarythyroid pages 2-4, capezzone2021familialnonmedullarythyroid pages 4-5, sanchezares2022susceptibilitygenesand pages 1-2, kamani2022geneticsusceptibilityto pages 11-12)

1. Disease information

Definition, category, and synonyms

Category: rare/familial endocrine malignancy; hereditary cancer predisposition; follicular-cell-derived thyroid carcinoma.

Common labels are familial nonmedullary thyroid carcinoma, familial non-medullary thyroid cancer, familial nonmedullary thyroid cancer, and—when all tumors are papillary—familial papillary thyroid carcinoma (FPTC). FPTC is a subset rather than a complete synonym because follicular, oncocytic/Hürthle-cell, and very rarely anaplastic histologies also occur. Reviews estimate histologic distributions of approximately 85–91% PTC, 6–9.7% follicular carcinoma, and much smaller proportions of Hürthle-cell or anaplastic carcinoma. (yang2016familialnonmedullarythyroid pages 1-2)

A useful exact abstract statement from Capezzone et al. (published online October 2020; journal issue 2021) is: “Familial non-medullary thyroid carcinoma (FNMTC), mainly of papillary histotype (FPTC), is defined by the presence of the disease in two or more first-degree relatives in the absence of other known familial syndromes.” DOI: 10.1007/s40618-020-01435-x. (capezzone2021familialnonmedullarythyroid pages 1-2)

Identifiers and coding

A definitive dedicated MONDO, OMIM, Orphanet, MeSH, ICD-10, or ICD-11 identifier was not established in the retrieved evidence. FNMTC is primarily a clinical familial-aggregation construct, and nonsyndromic disease is genetically heterogeneous rather than a single molecular entity. For production curation, the current releases of these terminologies should therefore be queried directly rather than assigning an unverified identifier. ICD coding ordinarily uses the thyroid malignancy code plus family-history/genetic-susceptibility modifiers; it does not encode the full FNMTC construct. Syndromic cases should additionally receive the identifier for the causal syndrome. (capezzone2021familialnonmedullarythyroid pages 4-5, sanchezares2022susceptibilitygenesand pages 1-2)

The following table provides conservative ontology recommendations; unverified IDs are deliberately not invented.

Table: This compact table lists practical knowledge-base annotations for familial nonmedullary thyroid carcinoma, including disease labels, suggested ontology terms, syndromic genes, mechanisms, and interventions. It also flags where the evidence is strong versus where identifiers or causal claims remain unverified or heterogeneous.

Source granularity

The report synthesizes aggregated disease-level resources, peer-reviewed reviews, family cohorts, tumor-series data, WGS analyses, and an observational registry. It is not derived from an individual EHR. One detailed Italian study included 33 unrelated families, 74 affected and 12 unaffected relatives; a separate WGS study examined 23 affected and three unaffected members of five families. (cirello2021clinicalandgenetic pages 1-2, srivastava2019wholegenomesequencing pages 2-5)

2. Etiology and risk factors

Genetic causation

Two etiologic classes should be separated:

1. Syndromic FNMTC: thyroid carcinoma is one manifestation of a defined inherited syndrome. Strong gene–syndrome associations include APC–familial adenomatous polyposis/Gardner syndrome, PTEN–PTEN hamartoma tumor syndrome/Cowden syndrome, DICER1 tumor-predisposition syndrome, PRKAR1A–Carney complex, and WRN–Werner syndrome. These are the most actionable germline findings. (capezzone2021familialnonmedullarythyroid pages 4-5, yang2016familialnonmedullarythyroid pages 2-4, sanchezares2022susceptibilitygenesand pages 1-2)
2. Nonsyndromic FNMTC: the commoner class, with complex monogenic, oligogenic, or polygenic susceptibility. Linkage regions include TCO/19p13.2, fPTC/PRN/1q21, NMTC1/2q21, MNG1, FTEN, 6q22, and 8q24. Candidate genes include FOXE1, SRGAP1, NKX2-1, HABP2, MAP2K5, SRRM2, DUOX2, PLCB1, BROX, POT1, ATM, CHEK2, NOP53, NDUFA13, TIMM44, ANXA3, NTN4, SERPINA1, FKBP10, PLEKHG5, P2RX5, and SAPCD1. Most associations are not sufficiently replicated for routine predictive testing. (yang2016familialnonmedullarythyroid pages 1-2, cirello2021clinicalandgenetic pages 2-3, kamani2022geneticsusceptibilityto pages 11-12)

Classic tumor drivers—BRAF, RAS, RET/PTC, NTRK, and PPARG rearrangements—are generally somatic rather than inherited FNMTC causes. Familial and sporadic tumors share these alterations. (capezzone2021familialnonmedullarythyroid pages 2-4, sanchezares2022susceptibilitygenesand pages 1-2)

Variant interpretation

• HABP2 p.Gly534Glu (G534E): initially proposed as a dominant susceptibility allele, but subsequent studies found inconsistent segregation and association. It should not be treated as a universally pathogenic FNMTC variant. (capezzone2021familialnonmedullarythyroid pages 4-5, yang2016familialnonmedullarythyroid pages 13-14)
• DUOX2 c.3607A>G, p.Tyr1203His: reported to co-segregate in one family and estimated as extremely rare—approximately 1/138,000—but absent from all 86 tested members of 33 independent Italian families. This is a family-level candidate, not a validated general cause. (cirello2021clinicalandgenetic pages 2-3, cirello2021clinicalandgenetic pages 1-2)
• FOXE1: the strongest repeatedly supported common susceptibility locus, but largely a moderate/low-effect risk locus rather than a highly penetrant diagnostic gene. Reviews describe FOXE1 penetrance as moderate-to-high for selected variants, while many GWAS loci have odds ratios only around 1.2–1.8. (capezzone2021familialnonmedullarythyroid pages 2-4, kamani2022geneticsusceptibilityto pages 14-15, kamani2022geneticsusceptibilityto pages 15-16)
• CHEK2, POT1, RET, TG, EWSR1 and other rare WGS candidates require segregation, population-frequency, functional, and independent-family validation before ACMG pathogenic classification. One WGS pipeline required MAF <0.1%, CADD-PHRED >10, family segregation, and predicted deleteriousness by ≥60% of in-silico tools; these filters prioritize candidates but do not establish pathogenicity. (srivastava2019wholegenomesequencing pages 5-7, srivastava2019wholegenomesequencing pages 2-5)

No robust disease-wide carrier frequency can be calculated because there is no single causal allele. Population frequency must be reported variant by variant using ancestry-matched gnomAD/TOPMed data at the time of clinical interpretation.

Environmental, lifestyle, and infectious factors

Family history is the defining risk factor. First-degree relatives have approximately 3-fold risk in a Swedish database analysis, 5.2–5.47-fold risk in another synthesis, and 8–10-fold risk in selected familial analyses; differences reflect case definitions, populations, and ascertainment. More than 90% of familial clusters contain only two affected members. (capezzone2021familialnonmedullarythyroid pages 2-4, capezzone2021familialnonmedullarythyroid pages 1-2, kamani2022geneticsusceptibilityto pages 1-2)

Ionizing radiation, especially childhood neck exposure, is an established risk factor for thyroid carcinoma generally and must be excluded as a shared explanation when classifying a nonsyndromic kindred. No FNMTC-specific quantitative gene–radiation interaction is established. Sex, age, iodine nutrition, obesity, and benign thyroid disease may alter background NMTC risk, but current evidence does not establish them as specific causes of familial clustering. There is no infectious cause and no demonstrated vaccine-preventable trigger. (sanchezares2022susceptibilitygenesand pages 1-2)

Protective factors and gene–environment interaction

No reproducible protective germline variant, diet, medication, or lifestyle intervention specifically prevents FNMTC. Avoiding unnecessary ionizing radiation is prudent general prevention, but does not eliminate inherited susceptibility. Evidence is insufficient to quantify specific gene–environment interactions. This is a major knowledge gap rather than evidence of no interaction.

3. Phenotypes

FNMTC can be asymptomatic until a nodule is detected. The clinical phenotype is otherwise that of differentiated thyroid carcinoma.

• Thyroid nodule/mass: clinical sign or imaging finding; often insidious and painless. Benign nodules, follicular adenoma, and multinodular goiter commonly coexist. Suggested HPO: Thyroid nodule, Multinodular goiter. (NCT01109420 chunk 1, sanchezares2022susceptibilitygenesand pages 1-2)
• Papillary thyroid carcinoma: malignant pathologic phenotype, usually classic or follicular variant; >85% of NMTC and 85–91% of familial tumors in summarized series. Suggested HPO: Thyroid carcinoma. (yang2016familialnonmedullarythyroid pages 1-2, kamani2022geneticsusceptibilityto pages 1-2)
• Multifocal/bilateral carcinoma: pathologic sign, variably frequent and often cited as enriched in familial tumors. In one 43-patient familial series, 56% were multifocal. Suggested HPO: Multifocal neoplasm; bilateral thyroid involvement should be separately annotated. (capezzone2021familialnonmedullarythyroid pages 6-7, cirello2021clinicalandgenetic pages 3-4)
• Extrathyroidal extension: locally invasive sign; 35% in the same series. Severity ranges from microscopic extension to invasion of neck structures. (cirello2021clinicalandgenetic pages 3-4)
• Cervical lymph-node metastasis: regional metastatic sign; 26% in the Italian series. Suggested HPO: Lymph node metastasis. (cirello2021clinicalandgenetic pages 3-4)
• Distant/lung metastasis: advanced manifestation; lung metastases occurred in 7% of that series. Suggested HPO: Pulmonary metastasis. (cirello2021clinicalandgenetic pages 3-4)
• Hashimoto thyroiditis association: reported more often in some familial pathology series, but its causal role and frequency are uncertain. (sanchezares2022susceptibilitygenesand pages 1-2)

Age and severity are variable. One clinical cohort had median diagnosis at 44 years, range 8–81 years. Reviews report younger presentation and possible anticipation, but ascertainment and intensified surveillance can produce apparent anticipation. (cirello2021clinicalandgenetic pages 3-4, kamani2022geneticsusceptibilityto pages 2-4)

Quality-of-life effects are primarily those of thyroid cancer and treatment: fear of recurrence, repeated neck imaging and laboratory surveillance, lifelong levothyroxine after total thyroidectomy, and possible hypoparathyroidism, voice impairment, or treatment-related fatigue. Retrieved evidence did not provide validated FNMTC-specific EQ-5D, SF-36, or PROMIS estimates; extrapolation from sporadic differentiated thyroid cancer should be labeled indirect.

4. Genetic and molecular information

Inheritance, penetrance, and expressivity

Nonsyndromic families often appear autosomal dominant, but with incomplete, age-dependent penetrance and marked variable expressivity; polygenic inheritance remains plausible. There is no established role for recessive inheritance, mitochondrial transmission, repeat expansion, germline mosaicism, or consanguinity in typical FNMTC. Founder effects may exist for individual variants but are not a general feature. (capezzone2021familialnonmedullarythyroid pages 2-4, capezzone2021familialnonmedullarythyroid pages 4-5)

Clinical anticipation has been reported, with second generations presenting younger and sometimes more severely. It is not proven to represent a repeat-expansion mechanism; surveillance bias and changing diagnostic intensity are important alternatives. (yang2016familialnonmedullarythyroid pages 1-2, kamani2022geneticsusceptibilityto pages 2-4)

Epigenetic and telomere findings

Shorter telomere length and imbalance of the telomere–telomerase system have been reported in familial cases and may modify susceptibility. Differential activity of miR-886-3p and miR-20a has also been proposed. These remain research biomarkers, not validated diagnostic tests. No reproducible FNMTC-specific methylation or histone-modification signature is ready for clinical use. (capezzone2021familialnonmedullarythyroid pages 4-5, cirello2021clinicalandgenetic pages 2-3, yang2016familialnonmedullarythyroid pages 13-14)

Chromosomal abnormalities

Historical linkage regions are susceptibility intervals, not recurrent diagnostic structural variants. Tumor translocations such as RET/PTC and NTRK fusions can occur somatically. Routine constitutional karyotyping, FISH, or chromosomal microarray has low expected yield in isolated FNMTC unless additional congenital or syndromic features suggest a chromosome disorder. (yang2016familialnonmedullarythyroid pages 1-2, cirello2021clinicalandgenetic pages 3-4)

5. Environmental information

No toxin, occupational exposure, lifestyle pattern, or pathogen uniquely defines FNMTC. Shared radiation exposure must be considered in clustered families. Smoking and alcohol are not established FNMTC-specific factors; thyroid-cancer associations with body mass, diet, iodine status, and endocrine-disrupting chemicals remain general epidemiologic issues, not demonstrated explanations for familial transmission. Environmental annotations should therefore be represented as general thyroid-cancer modifiers with low disease specificity, not as confirmed FNMTC causes.

6. Mechanism and pathophysiology

Causal chain

A defensible current model is:

Inherited susceptibility—a high-penetrance syndromic defect or a family-specific combination of rare and common alleles—→ altered genome maintenance, developmental transcription, growth-factor signaling, telomere biology, or miRNA regulation → increased probability of acquiring somatic thyroid drivers → constitutive MAPK/ERK and/or PI3K/AKT signaling in thyroid follicular cells → proliferation, survival, clonal expansion, papillary/follicular carcinoma → multifocal local growth, cervical nodal spread, and occasionally distant metastasis. (srivastava2019wholegenomesequencing pages 5-7, srivastava2019wholegenomesequencing pages 19-21, sanchezares2022susceptibilitygenesand pages 1-2)

Upstream mechanisms depend on the syndrome: PTEN loss releases PI3K–AKT signaling; APC disruption alters Wnt/β-catenin regulation; DICER1 defects impair miRNA processing; PRKAR1A defects dysregulate cAMP–PKA signaling; WRN loss impairs DNA repair and genome stability. In nonsyndromic disease, pathway convergence is clearer than any shared initiating gene.

Genomic and molecular profiling

WGS of 23 affected and three unaffected individuals from five families reduced 91,427–207,873 raw variants per family to 31 prioritized coding and 39 regulatory-region candidates. Among 210 pathway-mappable genes, receptor-tyrosine-kinase and GPCR networks converged on MAPK/ERK and PI3K/AKT; AKT and ERK1/2 were network hubs. Thyroid cancer enrichment was statistically significant but ranked below many broad cancer functions, underscoring that pathway analysis is hypothesis-generating. (srivastava2019wholegenomesequencing pages 5-7, srivastava2019wholegenomesequencing pages 2-5, srivastava2019wholegenomesequencing pages 16-19, srivastava2019wholegenomesequencing pages 19-21)

Tumor profiling in a familial series assayed BRAF V600E, RAS, AKT1, PIK3CA, EIF1AX, TERT-promoter hotspots and RET/PTC/NTRK fusions. Familial and sporadic NMTC share morphology and somatic drivers; currently, the same molecularly matched therapies apply. (cirello2021clinicalandgenetic pages 3-4, sanchezares2022susceptibilitygenesand pages 1-2)

No validated FNMTC-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or integrated multi-omic signature was identified. These technologies are active in thyroid-cancer research, but familial status has not yet yielded a reproducible clinical classifier.

Ontology suggestions

• Cell type: thyroid follicular cell, CL:0000501.
• Anatomy: thyroid gland, UBERON:0002046; cervical lymph nodes and lung for metastatic sites.
• Processes: MAPK cascade, GO:0000165; cell population proliferation, GO:0008283; PI3K–AKT signaling, DNA-damage response, miRNA processing, telomere maintenance, apoptotic signaling, and cell migration.
• Subcellular sites: nucleus for transcription/DNA repair/telomeres; plasma membrane and cytosol for RTK–RAS–MAPK and PI3K–AKT signaling; no FNMTC-specific organelle lesion is established.

7. Anatomical structures affected

The primary organ is the thyroid gland, specifically follicular epithelium rather than calcitonin-producing parafollicular C cells. Tumors may be unilateral or bilateral and unifocal or multifocal. Regional disease involves the central and lateral cervical lymph nodes; advanced disease may affect lung, bone, or other distant sites. The endocrine system is primary; respiratory, skeletal, and neurologic systems are involved only through local invasion, metastasis, or treatment complications. (capezzone2021familialnonmedullarythyroid pages 6-7, cirello2021clinicalandgenetic pages 3-4)

At the tissue level, affected structures include thyroid follicles, papillary tumor epithelium, tumor stroma, lymphatic vessels, and metastatic lymph-node parenchyma. Relevant GO cellular compartments include nucleus, chromosome/telomere, cytoplasm, plasma membrane, and receptor-signaling complexes.

8. Temporal development

Onset is typically insidious and adult, but pediatric and geriatric presentations occur; the documented 8–81-year range demonstrates marked age variability. Earlier onset should increase suspicion of inherited susceptibility, particularly with multicentricity or bilaterality. (capezzone2021familialnonmedullarythyroid pages 6-7, cirello2021clinicalandgenetic pages 3-4)

Course follows differentiated thyroid-cancer staging rather than a separate FNMTC staging system: localized intrathyroidal tumor → regional nodal disease → locally invasive or distant metastatic disease. Many PTCs are indolent, although familial cohorts can show more adverse features at diagnosis. Treatment-induced remission is common; biochemical or structural persistence/recurrence can occur. No credible spontaneous-remission pattern is established.

The critical intervention window is before clinically consequential nodal or distant spread, but overdiagnosis of indolent microcarcinoma is a countervailing harm. That balance explains disagreement over ultrasound screening.

9. Inheritance and population

FNMTC accounts for approximately 3–9%, nearly 10%, or 5–15% of thyroid/NMTC cases across reviews; variation reflects definition and denominator. Syndromic cases account for about 5% of familial disease, leaving approximately 95% classified as nonsyndromic. FNMTC-specific incidence per 100,000 is not reliably established. (yang2016familialnonmedullarythyroid pages 1-2, capezzone2021familialnonmedullarythyroid pages 1-2, kamani2022geneticsusceptibilityto pages 1-2)

Women predominate, as in sporadic differentiated thyroid cancer. In one familial clinical series, 38/43 patients (88%) were female and five male. This does not establish a universal sex ratio because of referral and family ascertainment. (cirello2021clinicalandgenetic pages 3-4)

No ethnicity is uniquely affected. GWAS effect sizes and rare-variant frequencies differ by ancestry, making ancestry-matched controls essential. No general carrier frequency is meaningful for a genetically heterogeneous trait.

10. Diagnostics

Clinical evaluation

Diagnosis begins with a three-generation pedigree, pathology confirmation in affected relatives, assessment of radiation exposure, and examination for syndromic features. Neck ultrasonography characterizes thyroid nodules and cervical lymph nodes. Suspicious nodules undergo ultrasound-guided fine-needle aspiration; cytology is classified using standard thyroid systems, with molecular testing used for indeterminate nodules where clinically appropriate. Serum TSH guides nodule evaluation but neither TSH nor thyroglobulin diagnoses FNMTC. Post-treatment thyroglobulin and anti-thyroglobulin antibodies are surveillance biomarkers.

Histopathology establishes papillary, follicular, or oncocytic carcinoma and documents multifocality, bilaterality, vascular/capsular invasion, extrathyroidal extension, margins, and nodal status. FNMTC and sporadic tumors cannot usually be distinguished morphologically or by common somatic mutations alone. (cirello2021clinicalandgenetic pages 3-4, sanchezares2022susceptibilitygenesand pages 1-2)

Genetic testing strategy

1. If syndromic features are present: use phenotype-directed germline testing—e.g., APC, PTEN, DICER1, PRKAR1A, WRN—with deletion/duplication analysis where appropriate. A multigene hereditary-cancer panel can be efficient when phenotypes overlap. (yang2016familialnonmedullarythyroid pages 2-4, sanchezares2022susceptibilitygenesand pages 1-2)
2. If apparently isolated nonsyndromic FNMTC: pre-test counseling should explain that no validated routine predictive panel explains most families. WES/WGS is most appropriate in research or carefully selected ≥3-case families, ideally sequencing multiple affected and unaffected relatives with segregation analysis. (yang2016familialnonmedullarythyroid pages 13-14, srivastava2019wholegenomesequencing pages 2-5, kamani2022geneticsusceptibilityto pages 14-15)
3. CMA, karyotype, FISH, mitochondrial sequencing, and repeat-expansion testing: not routine unless another phenotype supplies an independent indication.
4. Tumor sequencing/liquid biopsy: useful for therapy selection in advanced disease, not for proving familial causation. A tumor variant requires matched normal testing before it can be called germline.

Clinical criteria and differential diagnosis

Two first-degree relatives meet the conventional definition, but three affected relatives provide much greater specificity. Differential diagnoses include sporadic coincidental PTC; medullary thyroid carcinoma/MEN2; radiation-associated thyroid cancer; metastasis to thyroid; and syndromic NMTC due to PTEN, APC, DICER1, PRKAR1A, WRN, or other cancer syndromes. (yang2016familialnonmedullarythyroid pages 13-14, sanchezares2022susceptibilitygenesand pages 1-2)

11. Outcomes and prognosis

Whether FNMTC is intrinsically more aggressive remains unresolved. Some studies report younger age, larger or multifocal tumors, more extrathyroidal extension, nodal metastases, recurrence, and reduced survival; matched studies find little difference. The Italian series found a significantly more aggressive presentation but not a worse outcome after appropriate treatment. Reviews likewise report no consistent mortality or recurrence difference. (yang2016familialnonmedullarythyroid pages 1-2, capezzone2021familialnonmedullarythyroid pages 1-2, cirello2021clinicalandgenetic pages 1-2, kamani2022geneticsusceptibilityto pages 1-2)

Accordingly, no reliable FNMTC-specific 5- or 10-year survival estimate can be supplied from the retrieved evidence. Prognosis should use standard differentiated-thyroid-cancer variables: age, histologic subtype, tumor size, gross extrathyroidal extension, completeness of resection, nodal burden, distant metastasis, radioiodine avidity, thyroglobulin response, and actionable somatic genotype. Family history alone is not a validated basis for assigning a worse stage.

Long-term morbidity is more commonly treatment-related or surveillance-related than disabling tumor burden: hypothyroidism, hypoparathyroidism, recurrent-laryngeal-nerve injury, neck discomfort, salivary effects from radioiodine, anxiety, and financial/psychosocial burden. FNMTC-specific disability and quality-of-life statistics remain insufficient.

12. Treatment and applications

FNMTC is treated according to standard differentiated thyroid-cancer risk stratification. Current ATA-aligned reviews do not recommend a different therapeutic approach solely because of family history. (capezzone2021familialnonmedullarythyroid pages 6-7)

• Surgery: lobectomy or total thyroidectomy according to tumor size, bilaterality/multifocality, nodal disease, molecular/pathologic risk, and patient preference; therapeutic compartment-oriented neck dissection for proven nodal metastases. In one referral series, 93% underwent total thyroidectomy, but this is not evidence that all FNMTC requires total thyroidectomy. Suggested NCIT: Thyroidectomy, Lobectomy, Neck Dissection. (cirello2021clinicalandgenetic pages 3-4)
• Radioactive iodine (I-131): selected after surgery according to recurrence risk and radioiodine avidity, not automatically for familial status. Suggested NCIT: Radioactive Iodine Therapy; CHEBI annotation should use the curated iodide/I-131 entity.
• Levothyroxine/TSH suppression: replacement after total thyroidectomy and risk-adapted TSH suppression. Suggested NCIT: Thyroid Hormone Replacement Therapy, TSH Suppression Therapy.
• Advanced radioiodine-refractory disease: molecularly selected kinase inhibition follows ordinary DTC practice—RET or NTRK inhibitors for corresponding fusions, BRAF/MEK-directed approaches in appropriate BRAF-altered disease, and multikinase inhibitors for progressive refractory disease. Familial and sporadic tumors currently share these therapeutic rules because their somatic drivers overlap. Suggested NCIT: Kinase Inhibitor Therapy, Targeted Therapy. (sanchezares2022susceptibilitygenesand pages 1-2)
• Immunotherapy, gene therapy, cell therapy, RNA therapy, or prophylactic thyroidectomy: no FNMTC-specific approved indication. Prophylactic thyroidectomy is not recommended for nonsyndromic FNMTC in the manner used for RET-positive MEN2.

There is no established FNMTC pharmacogenomic rule. Somatic genotype guides targeted efficacy; germline findings primarily guide syndrome surveillance rather than drug metabolism.

13. Prevention and screening

Primary prevention

No intervention can remove inherited susceptibility. Avoid unnecessary childhood neck radiation and manage general health risks, but no diet, vaccine, supplement, or prophylactic drug has demonstrated FNMTC prevention.

Secondary prevention

Routine population ultrasound screening is not recommended. Universal ultrasound screening of all relatives is also controversial: one prospective study found thyroid cancer in 4.6% of screened at-risk relatives from two-case families, approximately comparable to detection in heavily imaged populations. Major reviews report that ATA, NCCN, and ESMO have not endorsed routine genetic screening of nonsyndromic relatives because evidence is insufficient. (capezzone2021familialnonmedullarythyroid pages 4-5, kamani2022geneticsusceptibilityto pages 2-4, kamani2022geneticsusceptibilityto pages 14-15)

A reasonable expert approach is individualized counseling and clinical neck examination, with lower threshold for ultrasound in families with ≥3 affected members, unusually young onset, aggressive disease, palpable abnormalities, or a known syndrome. Families with only two older-onset micro-PTCs carry substantial risk of coincidental clustering and overdiagnosis. (yang2016familialnonmedullarythyroid pages 13-14, capezzone2021familialnonmedullarythyroid pages 6-7)

Real-world implementation

The NIDDK prospective observational cohort NCT01109420, “Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer,” began August 12, 2010 and was listed as recruiting with estimated enrollment of 500. It accepts affected families and unaffected relatives, performs family history, examination, laboratory testing and imaging, and annually re-screens unaffected participants without malignant tumors. Objectives include defining natural history, optimizing screening, and identifying susceptibility genes. ClinicalTrials.gov: NCT01109420. (NCT01109420 chunk 1)

Tertiary prevention and counseling

Risk-adapted postoperative surveillance, thyroglobulin monitoring, cervical ultrasound, appropriate radioiodine use, and treatment of persistent/recurrent disease prevent complications. Genetic counseling should address uncertain penetrance, limitations of negative testing, possible incidental findings, and syndrome-specific cancer surveillance. Reproductive testing or preimplantation genetic testing is technically meaningful only when a clearly pathogenic germline variant has been established; it is not appropriate for an unvalidated candidate allele.

14. Other species and natural disease

Spontaneous follicular-cell-derived thyroid tumors occur in companion and laboratory animals, but the retrieved literature did not establish a naturally occurring veterinary syndrome orthologous to human nonsyndromic FNMTC. There is no zoonotic transmission. Human susceptibility genes have conserved orthologs in mouse and other vertebrates, but conservation of a pathway does not establish a homologous familial disease.

Suggested taxonomy annotations for general comparative research include Homo sapiens (NCBI Taxon 9606), Mus musculus (10090), Rattus norvegicus (10116), and Danio rerio (7955). Breed-specific VBO annotations are not supported for FNMTC.

15. Model organisms

No single model faithfully reproduces genetically heterogeneous nonsyndromic FNMTC. Available thyroid-cancer models instead interrogate downstream mechanisms:

• genetically engineered mice expressing thyroid-specific BRAF V600E, RET/PTC, RAS, or altered PTEN/PI3K signaling;
• thyroid cancer cell lines and patient-derived cultures/organoids;
• xenograft or patient-derived xenograft models;
• CRISPR knock-in/knockout systems for candidate variants;
• zebrafish models for thyroid development and oncogenic signaling.

These models can reproduce follicular-cell transformation and MAPK/PI3K pathway activation, but generally model a somatic driver or one syndrome—not the incomplete penetrance, polygenic architecture, and within-family variability of human FNMTC. The most informative future design would combine a segregating human germline variant with a thyroid-specific somatic driver and longitudinal assessment of penetrance.

Recent developments and evidence limitations

The requested 2023–2024 priority yielded limited directly retrievable primary literature. A 2024 report proposed PAK4 as a susceptibility gene (DOI 10.1089/thy.2023.0564), but full evidence was unavailable in the retrieved corpus; it should therefore be treated as emerging, not yet independently validated, and not assigned as an established causal gene. The strongest accessible contemporary syntheses were published in 2021–2022, while the ongoing NIH cohort supplies current implementation data.

Three overarching limitations should be retained in the knowledge base: (1) two-case families are contaminated by coincidental sporadic PTC; (2) many candidate-gene reports are single-family or underpowered and lack replication; and (3) screening changes apparent age, tumor size, and aggressiveness. Consequently, reported anticipation, penetrance, and familial–sporadic outcome differences should be annotated with ascertainment-bias qualifiers.

Key sources and direct abstract quotations

• Capezzone et al., Journal of Endocrinological Investigation, published online October 2020/volume 2021, DOI 10.1007/s40618-020-01435-x: “FNMTC is described as a polygenic disorder associated with multiple low- to moderate-penetrance susceptibility genes and incomplete penetrance.” (capezzone2021familialnonmedullarythyroid pages 1-2)
• Cirello et al., Frontiers in Endocrinology, January 2021, DOI 10.3389/fendo.2020.589340: “Familial tumors had a statistically significant more aggressive presentation at diagnosis, though not resulting in a worst outcome.” (cirello2021clinicalandgenetic pages 1-2)
• Sánchez-Ares et al., Frontiers in Endocrinology, February 2022, DOI 10.3389/fendo.2022.829103: “Non-syndromic familial non-medullary carcinoma has a complex and heterogeneous genetic basis involving several genes and loci with a monogenic or polygenic inheritance model.” (sanchezares2022susceptibilitygenesand pages 1-2)
• Kamani et al., Hereditary Cancer in Clinical Practice, March 2022, DOI 10.1186/s13053-022-00215-3: “The gene(s) responsible for the vast majority of non-syndromic FNMTC cases are yet to be identified.” (kamani2022geneticsusceptibilityto pages 1-2)

PMIDs were not exposed in the retrieved full-text metadata and therefore are not fabricated here. DOI links provide stable source resolution. The evidence base supports robust disease-level characterization, but not definitive assignment of most nonsyndromic candidate genes as pathogenic.

References

1. (yang2016familialnonmedullarythyroid pages 13-14): Samantha Peiling Yang and Joanne Ngeow. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocrine-related cancer, 23 12:R577-R595, Dec 2016. URL: https://doi.org/10.1530/erc-16-0067, doi:10.1530/erc-16-0067. This article has 140 citations and is from a domain leading peer-reviewed journal.

2. (sanchezares2022susceptibilitygenesand pages 1-2): María Sánchez-Ares, Soledad Cameselle-García, Ihab Abdulkader-Nallib, Gemma Rodríguez-Carnero, Carolina Beiras-Sarasquete, José Antonio Puñal-Rodríguez, and José Manuel Cameselle-Teijeiro. Susceptibility genes and chromosomal regions associated with non-syndromic familial non-medullary thyroid carcinoma: some pathogenetic and diagnostic keys. Frontiers in Endocrinology, Feb 2022. URL: https://doi.org/10.3389/fendo.2022.829103, doi:10.3389/fendo.2022.829103. This article has 19 citations.

3. (kamani2022geneticsusceptibilityto pages 1-2): Tina Kamani, Parsa Charkhchi, Afshan Zahedi, and Mohammad R. Akbari. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hereditary Cancer in Clinical Practice, Mar 2022. URL: https://doi.org/10.1186/s13053-022-00215-3, doi:10.1186/s13053-022-00215-3. This article has 37 citations and is from a peer-reviewed journal.

4. (capezzone2021familialnonmedullarythyroid pages 2-4): M. Capezzone, E. Robenshtok, E. Robenshtok, S. Cantara, and M. G. Castagna. Familial non-medullary thyroid cancer: a critical review. Journal of Endocrinological Investigation, 44:943-950, Oct 2021. URL: https://doi.org/10.1007/s40618-020-01435-x, doi:10.1007/s40618-020-01435-x. This article has 81 citations and is from a peer-reviewed journal.

5. (capezzone2021familialnonmedullarythyroid pages 4-5): M. Capezzone, E. Robenshtok, E. Robenshtok, S. Cantara, and M. G. Castagna. Familial non-medullary thyroid cancer: a critical review. Journal of Endocrinological Investigation, 44:943-950, Oct 2021. URL: https://doi.org/10.1007/s40618-020-01435-x, doi:10.1007/s40618-020-01435-x. This article has 81 citations and is from a peer-reviewed journal.

6. (kamani2022geneticsusceptibilityto pages 11-12): Tina Kamani, Parsa Charkhchi, Afshan Zahedi, and Mohammad R. Akbari. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hereditary Cancer in Clinical Practice, Mar 2022. URL: https://doi.org/10.1186/s13053-022-00215-3, doi:10.1186/s13053-022-00215-3. This article has 37 citations and is from a peer-reviewed journal.

7. (yang2016familialnonmedullarythyroid pages 1-2): Samantha Peiling Yang and Joanne Ngeow. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocrine-related cancer, 23 12:R577-R595, Dec 2016. URL: https://doi.org/10.1530/erc-16-0067, doi:10.1530/erc-16-0067. This article has 140 citations and is from a domain leading peer-reviewed journal.

8. (capezzone2021familialnonmedullarythyroid pages 1-2): M. Capezzone, E. Robenshtok, E. Robenshtok, S. Cantara, and M. G. Castagna. Familial non-medullary thyroid cancer: a critical review. Journal of Endocrinological Investigation, 44:943-950, Oct 2021. URL: https://doi.org/10.1007/s40618-020-01435-x, doi:10.1007/s40618-020-01435-x. This article has 81 citations and is from a peer-reviewed journal.

9. (NCT01109420 chunk 1): Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2010. ClinicalTrials.gov Identifier: NCT01109420

10. (cirello2021clinicalandgenetic pages 3-4): Valentina Cirello, Carla Colombo, Olga Karapanou, Gabriele Pogliaghi, Luca Persani, and Laura Fugazzola. Clinical and genetic features of a large monocentric series of familial non-medullary thyroid cancers. Frontiers in Endocrinology, Jan 2021. URL: https://doi.org/10.3389/fendo.2020.589340, doi:10.3389/fendo.2020.589340. This article has 10 citations.

11. (cirello2021clinicalandgenetic pages 1-2): Valentina Cirello, Carla Colombo, Olga Karapanou, Gabriele Pogliaghi, Luca Persani, and Laura Fugazzola. Clinical and genetic features of a large monocentric series of familial non-medullary thyroid cancers. Frontiers in Endocrinology, Jan 2021. URL: https://doi.org/10.3389/fendo.2020.589340, doi:10.3389/fendo.2020.589340. This article has 10 citations.

12. (srivastava2019wholegenomesequencing pages 5-7): Aayushi Srivastava, Abhishek Kumar, Sara Giangiobbe, Elena Bonora, Kari Hemminki, Asta Försti, and Obul Reddy Bandapalli. Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in mapk/erk and pi3k/akt signaling pathways. ArXiv, Oct 2019. URL: https://doi.org/10.20944/preprints201910.0154.v1, doi:10.20944/preprints201910.0154.v1. This article has 34 citations.

13. (srivastava2019wholegenomesequencing pages 19-21): Aayushi Srivastava, Abhishek Kumar, Sara Giangiobbe, Elena Bonora, Kari Hemminki, Asta Försti, and Obul Reddy Bandapalli. Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in mapk/erk and pi3k/akt signaling pathways. ArXiv, Oct 2019. URL: https://doi.org/10.20944/preprints201910.0154.v1, doi:10.20944/preprints201910.0154.v1. This article has 34 citations.

14. (yang2016familialnonmedullarythyroid pages 2-4): Samantha Peiling Yang and Joanne Ngeow. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocrine-related cancer, 23 12:R577-R595, Dec 2016. URL: https://doi.org/10.1530/erc-16-0067, doi:10.1530/erc-16-0067. This article has 140 citations and is from a domain leading peer-reviewed journal.

15. (capezzone2021familialnonmedullarythyroid pages 6-7): M. Capezzone, E. Robenshtok, E. Robenshtok, S. Cantara, and M. G. Castagna. Familial non-medullary thyroid cancer: a critical review. Journal of Endocrinological Investigation, 44:943-950, Oct 2021. URL: https://doi.org/10.1007/s40618-020-01435-x, doi:10.1007/s40618-020-01435-x. This article has 81 citations and is from a peer-reviewed journal.

16. (kamani2022geneticsusceptibilityto pages 14-15): Tina Kamani, Parsa Charkhchi, Afshan Zahedi, and Mohammad R. Akbari. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hereditary Cancer in Clinical Practice, Mar 2022. URL: https://doi.org/10.1186/s13053-022-00215-3, doi:10.1186/s13053-022-00215-3. This article has 37 citations and is from a peer-reviewed journal.

17. (srivastava2019wholegenomesequencing pages 2-5): Aayushi Srivastava, Abhishek Kumar, Sara Giangiobbe, Elena Bonora, Kari Hemminki, Asta Försti, and Obul Reddy Bandapalli. Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in mapk/erk and pi3k/akt signaling pathways. ArXiv, Oct 2019. URL: https://doi.org/10.20944/preprints201910.0154.v1, doi:10.20944/preprints201910.0154.v1. This article has 34 citations.

18. (cirello2021clinicalandgenetic pages 2-3): Valentina Cirello, Carla Colombo, Olga Karapanou, Gabriele Pogliaghi, Luca Persani, and Laura Fugazzola. Clinical and genetic features of a large monocentric series of familial non-medullary thyroid cancers. Frontiers in Endocrinology, Jan 2021. URL: https://doi.org/10.3389/fendo.2020.589340, doi:10.3389/fendo.2020.589340. This article has 10 citations.

19. (kamani2022geneticsusceptibilityto pages 15-16): Tina Kamani, Parsa Charkhchi, Afshan Zahedi, and Mohammad R. Akbari. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hereditary Cancer in Clinical Practice, Mar 2022. URL: https://doi.org/10.1186/s13053-022-00215-3, doi:10.1186/s13053-022-00215-3. This article has 37 citations and is from a peer-reviewed journal.

20. (kamani2022geneticsusceptibilityto pages 2-4): Tina Kamani, Parsa Charkhchi, Afshan Zahedi, and Mohammad R. Akbari. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hereditary Cancer in Clinical Practice, Mar 2022. URL: https://doi.org/10.1186/s13053-022-00215-3, doi:10.1186/s13053-022-00215-3. This article has 37 citations and is from a peer-reviewed journal.

21. (srivastava2019wholegenomesequencing pages 16-19): Aayushi Srivastava, Abhishek Kumar, Sara Giangiobbe, Elena Bonora, Kari Hemminki, Asta Försti, and Obul Reddy Bandapalli. Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in mapk/erk and pi3k/akt signaling pathways. ArXiv, Oct 2019. URL: https://doi.org/10.20944/preprints201910.0154.v1, doi:10.20944/preprints201910.0154.v1. This article has 34 citations.

Artifacts

• Edison artifact artifact-00